Stock EXTX EXACT THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

EXACT Therapeutics

Equities

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 03:36:07 2024-04-25 am EDT 		5-day change 1st Jan Change
6.8 NOK -2.86% Intraday chart for EXACT Therapeutics -2.86% -43.33%
Apr. 19 EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023 CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023 CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study CI
EXACT Therapeutics AS Announces Management Changes CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022 CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24% MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022 CI
EXACT Therapeutics Appoints Chief Medical Officer MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022 CI
Norway's Exact Therapeutics Appoints New CFO MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022 CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project MT

Chart EXACT Therapeutics

Chart EXACT Therapeutics
More charts

Company Profile

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.
Sector
Biotechnology & Medical Research
Calendar
2024-06-06 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EXACT THERAPEUTICS Stock EXACT Therapeutics
-43.33% 20.42M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.06% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+5.35% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.04% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.97% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.28% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.11% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.10% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.04% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EXTX Stock
  4. News EXACT Therapeutics
  5. Exact Therapeutics : Appoints New CFO